Leveraging Insulin Sensitizers to Correct the Metabolic Dysfunction Associated with Obesity

Time: 2:30 pm
day: Day Two


  • Metabolic reprogramming through a new mitochondrial target for TZD insulin sensitizers facilitated develop of new insulin sensitizers
  • New agents lack tolerability issues of direct transcriptional activators and can fully engage insulin sensitizing pharmacology through the newly identified mitochondrial target
  • Metabolic reprogramming occurs in multiple cell types to produce a pleiotropic pharmacology, which importantly includes improved response to viral infections